Teva's CGRP Migraine Med Hits a Stumbling Block Post author:Sam Post published:February 8, 2018 Post category:BioPharma It’s starting to feel like Teva can’t catch a break. Source: BioSpace You Might Also Like Bicycle Therapeutics Snags $52 Million to Take Early Stage Drugs Into Clinic May 31, 2017 Cambridge Biotech Startup Rubius Banks $120 Million, Hopes to Hire 60 New Staffers June 20, 2017 The Stunning Golden Parachutes of Juno's $9B Celgene Deal February 4, 2018
